dc.contributor.author |
Senaratne, W.V. |
en_US |
dc.contributor.author |
Pinidiyapathirage, M.J. |
en_US |
dc.contributor.author |
Perera, G.A.M.H.E. |
en_US |
dc.contributor.author |
Wickremasinghe, A.R. |
en_US |
dc.date.accessioned |
2014-10-29T09:24:43Z |
|
dc.date.available |
2014-10-29T09:24:43Z |
|
dc.date.issued |
2006 |
en_US |
dc.identifier.citation |
The Ceylon Medical Journal. 2006; 51(1): pp.9-14 |
en_US |
dc.identifier.issn |
0009-0875 (Print) |
en_US |
dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/1762 |
|
dc.description |
Indexed in MEDLINE |
|
dc.description.abstract |
OBJECTIVE: To assess the incidence of anti-tuberculosis (TB) drug induced hepatitis (AIH) in Sri Lankan patients, determine risk factors of AIH, and to address management options in AIH. DESIGN: A prospective study. SETTING: Chest Hospital, Welisara, Sri Lanka, from April 2001 to April 2002. PATIENTS: Seven hundred and eighty three patients with a confirmed diagnosis of TB and resident in the Colombo and Gampaha districts who presented to Chest Hospital, Welisara, Sri Lanka. METHODS: WHO recommended treatment was commenced in all cases. AIH was diagnosed when patients complained of decreased appetite with nausea or vomiting and elevated serum bilirubin (SB; >1.1 mg/dL) or elevated serum alanine transferase (ALT; > 3 times upper limit of normal).RESULTS: Of 783 enrolled patients, 74 (9.5%) developed AIH, the majority (58%) developing AIH within the first 2 weeks of the intensive phase of treatment. AIH was more common among patients over 60 years (p = 0.018), who developed pulmonary TB (p = 0.028), and in patients weighing 33-55 kg (p = 0.004). Age, weight and rifampicin overdosage were significant predictors of AIH. Of the 74 AIH patients, standard treatment was restarted in 60, treatment modified in six, two defaulted and six died. CONCLUSIONS: The incidence of AIH in Sri Lanka is 9.5% in treated patients. AIH was associated with age, low body weight and rifampicin over dosage. |
en_US |
dc.publisher |
Sri Lanka Medical Association |
en_US |
dc.subject |
Tuberculosis-drug therapy |
|
dc.subject |
Antitubercular Agents-adverse effects |
|
dc.subject |
Streptomycin-adverse effects |
|
dc.subject |
Isoniazid-adverse effects |
|
dc.subject |
Rifampin-adverse effects |
|
dc.subject |
Drug-Induced Liver Injury-epidemiology |
|
dc.subject |
Drug-Induced Liver Injury-etiology |
|
dc.subject |
Risk Factors |
|
dc.subject |
Prospective Studies |
|
dc.subject |
Sri Lanka-epidemiology |
|
dc.title |
Anti-tuberculosis drug inducd hepatitis:a Sri Lankan experience |
en_US |
dc.type |
Research Article |
en_US |
dc.identifier.department |
Public Health |
en_US |
dc.creator.corporateauthor |
Sri Lanka Medical Association |
en_US |